Scotiabank raises Microsoft target to 615 from 510
Scotiabank raised its price target on Microsoft to 615 from 510.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
24 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Wells Fargo Raises Microsoft Price Target to $725
Wells Fargo has added Microsoft to its fourth-quarter Tactical Ideas list and raised its price target on the software giant to $725 from $700.
Wells Fargo Raises Microsoft Price Target to $725 From $700
Wells Fargo analyst Michael Turrin raised the price target on Microsoft to $725 from $700, maintaining a neutral rating.
Stifel Raises Microsoft To Buy From Hold; Raises Target Price To $575 From $530
Stifel Raises Microsoft To Buy From Hold; Raises Target Price To $575 From $530
Oppenheimer raises Microsoft target to $570 for 2027
Oppenheimer analyst Brian Schwartz raised his Microsoft price target to $570 from $515 and maintained an Outperform rating after meeting with company management, keeping a positive view of MSFT’s growth prospects.
Analyst Sees More Upside for Microsoft Stock Following Management Meeting
Microsoft Corp (NASDAQ: MSFT ) shares are trading slightly lower Tuesday, pulling back modestly even as Oppenheimer reiterated an Outperform rating and raised the price target on the stock. Here’s what you should know. Microsoft stock is trending. What’s ahead for MSFT stock? Oppenheimer Raises Microsoft Price Target t
Redburn raises Microsoft price target to $440, keeps Neutral
Rothschild & Co Redburn lifted its MSFT price target to $440 from $400 while maintaining a Neutral rating, citing higher valuation multiples after a broader software-as-a-service re-rating.
Stifel raises Microsoft target to $530, keeps stock at Neutral
Stifel analyst Brad Reback raised his Microsoft target to $530 from $450, an increase of nearly 18%, after meetings with executives, while keeping the stock at Neutral and not ready to recommend buying.
DocuSign raises fiscal 2027 ARR guidance after Q2 results
DocuSign reported Q2 revenue of $876 million, up 9% year over year, with a 32% operating margin and about $300 million in free cash flow. It also raised fiscal 2027 ARR guidance and said IAM now accounts for 15.1% of total ARR.
BofA raises MSFT price target to $600 from $500
BofA lifted its MSFT price target to $600 from $500 and maintained a Buy rating.
Microsoft internal spreadsheet shows Cloud and AI stock awards up to $1.4 million
A reported internal compensation spreadsheet reviewed by Business Insider showed Microsoft Cloud + AI employees self-reporting stock awards as high as $1.4 million, alongside wide ranges for base pay, bonuses and equity.
Microsoft Price Target Raised
Wells Fargo raises Microsoft price target to $700 from $650
SpaceX Stock Primed for Massive 122% Upside, JPMorgan Says
Shares of SpaceX (NASDAQ: SPCX ) fell almost 14% Wednesday as the company’s second-quarter financial results, which revealed higher-than-expected capital spending, undermined investor sentiment. One analyst is pleased with the rockets-to-AI firm’s updated post-IPO goals. The SpaceX Analyst JPMorgan’s Doug Anmuth reiter
Microsoft target raised to $595 by HSBC
HSBC raises Microsoft target price
Microsoft Target Raised To $600
Citigroup raises Microsoft target price
Microsoft Raises Price Target
Piper Sandler raises Microsoft target
Nebius Stock Bounces Off $164 Support: What's Driving the Rebound?
Nebius Group NV (NASDAQ: NBIS ) shares are up more than 5% during Monday’s premarket session as traders lean back into high-multiple AI infrastructure names after last week’s risk-off rotation, with high-multiple artificial intelligence names also getting a lift from firmer S&P 500 futures. Here’s what investors need t
Bulls and Bears: IBM, Super Micro, Tesla
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks endured a difficult week as a renewed surge in oil prices and disappointing reactions to Big Tech earnings weighed heavily on investor sentiment. The S&P 500, Nasdaq Composite and Dow Jo
Oracle Faces Pressure: Data Center Costs and OpenAI Exposure Weigh on Stock
Oracle Corp (NYSE: ORCL ) stock traded lower on Wednesday as big-cap tech remains under pressure in a risk-off tape. The Nasdaq is down 0.59% while the S&P 500 has shed 0.16%. The stock drew scrutiny on CNBC’s "Fast Money" on Tuesday after traders discussed reports that data center cost overruns are weighing on the sto
Oracle Faces Pressure: Data Center Costs and OpenAI Exposure Weigh on Stock
Oracle Corp (NYSE: ORCL ) stock traded lower on Wednesday as big-cap tech remains under pressure in a risk-off tape. The Nasdaq is down 0.59% while the S&P 500 has shed 0.16%. The stock drew scrutiny on CNBC’s "Fast Money" on Tuesday after traders discussed reports that data center cost overruns are weighing on the sto
Elevance Health's Small Outlook Boost Disappoints, Stock Sinks
Elevance Health Inc. (NYSE: ELV ) on Wednesday reported second-quarter results that topped Wall Street estimates and raised its full-year adjusted earnings and operating cash flow guidance, supported by higher premium yields and continued growth in its Carelon business. Adjusted earnings came in at $7.45 per share, bea
Bloom Energy Stock Extends Rebound Following CEO Comments: What Investors Need To Know
Bloom Energy Corp (NYSE: BE ) shares are trading higher on Tuesday as investors lean into the AI-power infrastructure theme after fresh CEO comments framed legacy turbines as a poor fit for hyperscale data-center demand. Bloom Energy stock is charging ahead with explosive momentum. What’s fueling BE momentum? What Is D
Nasdaq Posts Sharpest Decline
Nasdaq Composite posts its sharpest weekly decline in months, weighed down by weakness in mega-cap technology stocks
EU Probes Sanofi
The European Commission launches an antitrust investigation into Sanofi over allegedly misleading flu vaccine claims